新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）突变体对疫苗研发的挑战。 - Suppr

The challenge of emerging SARS-CoV-2 mutants to vaccine development.

作者信息

Li Rong, Liu Jun, Zhang Hui

机构信息

Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.

出版信息

J Genet Genomics. 2021 Feb 20;48(2):102-106. doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20.

DOI:10.1016/j.jgg.2021.03.001

PMID:33994322

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8056881/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c4/8056881/1d28bf71d765/gr1_lrg.jpg

相似文献

The challenge of emerging SARS-CoV-2 mutants to vaccine development.

J Genet Genomics. 2021 Feb 20;48(2):102-106. doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20.

COVID-19 vaccine breakthrough infections.

Science. 2021 Dec 24;374(6575):1561-1562. doi: 10.1126/science.abl8487. Epub 2021 Dec 23.

Variant-proof vaccines - invest now for the next pandemic.

Nature. 2021 Feb;590(7846):386-388. doi: 10.1038/d41586-021-00340-4.

The emerging plasticity of SARS-CoV-2.

Science. 2021 Mar 26;371(6536):1306-1308. doi: 10.1126/science.abg4493.

SARS-CoV-2 evolution and vaccines: cause for concern?

Lancet Respir Med. 2021 Apr;9(4):333-335. doi: 10.1016/S2213-2600(21)00075-8. Epub 2021 Jan 29.

Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.

PLoS Pathog. 2021 Mar 25;17(3):e1009406. doi: 10.1371/journal.ppat.1009406. eCollection 2021 Mar.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.

Fast-spreading COVID variant can elude immune responses.

Nature. 2021 Jan;589(7843):500-501. doi: 10.1038/d41586-021-00121-z.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.

引用本文的文献

Impact of Vaccination on Intra-Host Genetic Diversity of Patients Infected with SARS-CoV-2 Gamma Lineage.

Viruses. 2024 Sep 26;16(10):1524. doi: 10.3390/v16101524.

Whole genome sequencing and phylogenetic analysis of SARS-CoV-2 strains isolated during the COVID-19 pandemic in Nigeria.

IJID Reg. 2024 Jan 17;10:174-178. doi: 10.1016/j.ijregi.2024.01.005. eCollection 2024 Mar.

Bayesian Inference Elucidates the Catalytic Competency of the SARS-CoV-2 Main Protease 3CL.

Anal Chem. 2023 Oct 10;95(40):14981-14989. doi: 10.1021/acs.analchem.3c02459. Epub 2023 Sep 26.

Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness HSPGs: A review and mechanistic hypothesis.

Front Public Health. 2022 Aug 24;10:952916. doi: 10.3389/fpubh.2022.952916. eCollection 2022.

A Biosensor Platform for Point-of-Care SARS-CoV-2 Screening.

Biosensors (Basel). 2022 Jul 3;12(7):487. doi: 10.3390/bios12070487.

Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV.

Med Oncol. 2022 Apr 10;39(6):104. doi: 10.1007/s12032-022-01700-4.

Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.

Clin Microbiol Infect. 2022 Jun;28(6):882.e1-882.e7. doi: 10.1016/j.cmi.2022.02.030. Epub 2022 Mar 3.

ACE2-based capacitance sensor for rapid native SARS-CoV-2 detection in biological fluids and its correlation with real-time PCR.

Biosens Bioelectron. 2022 Apr 15;202:114021. doi: 10.1016/j.bios.2022.114021. Epub 2022 Jan 21.

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.

Cell Rep. 2022 Jan 18;38(3):110256. doi: 10.1016/j.celrep.2021.110256. Epub 2021 Dec 23.

In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern.

Int J Pept Res Ther. 2022;28(1):28. doi: 10.1007/s10989-021-10339-0. Epub 2021 Dec 13.

本文引用的文献

Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2.

Nat Commun. 2021 Sep 27;12(1):5654. doi: 10.1038/s41467-021-25903-x.

Updated SARS-CoV-2 single nucleotide variants and mortality association.

J Med Virol. 2021 Dec;93(12):6525-6534. doi: 10.1002/jmv.27191. Epub 2021 Jul 16.

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.

Nat Commun. 2021 May 17;12(1):2893. doi: 10.1038/s41467-021-23173-1.

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.

A human coronavirus evolves antigenically to escape antibody immunity.

PLoS Pathog. 2021 Apr 8;17(4):e1009453. doi: 10.1371/journal.ppat.1009453. eCollection 2021 Apr.

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.

Science. 2021 Mar 25;372(6549):1413-8. doi: 10.1126/science.abg9175.

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.

The effect of spike mutations on SARS-CoV-2 neutralization.

Cell Rep. 2021 Mar 23;34(12):108890. doi: 10.1016/j.celrep.2021.108890. Epub 2021 Mar 6.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.

Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The challenge of emerging SARS-CoV-2 mutants to vaccine development.

J Genet Genomics. 2021 Feb 20;48(2):102-106. doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20.

COVID-19 vaccine breakthrough infections.

Science. 2021 Dec 24;374(6575):1561-1562. doi: 10.1126/science.abl8487. Epub 2021 Dec 23.

Variant-proof vaccines - invest now for the next pandemic.

Nature. 2021 Feb;590(7846):386-388. doi: 10.1038/d41586-021-00340-4.

The emerging plasticity of SARS-CoV-2.

Science. 2021 Mar 26;371(6536):1306-1308. doi: 10.1126/science.abg4493.

SARS-CoV-2 evolution and vaccines: cause for concern?

Lancet Respir Med. 2021 Apr;9(4):333-335. doi: 10.1016/S2213-2600(21)00075-8. Epub 2021 Jan 29.

Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.

PLoS Pathog. 2021 Mar 25;17(3):e1009406. doi: 10.1371/journal.ppat.1009406. eCollection 2021 Mar.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.

Fast-spreading COVID variant can elude immune responses.

Nature. 2021 Jan;589(7843):500-501. doi: 10.1038/d41586-021-00121-z.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.

引用本文的文献

Impact of Vaccination on Intra-Host Genetic Diversity of Patients Infected with SARS-CoV-2 Gamma Lineage.

Viruses. 2024 Sep 26;16(10):1524. doi: 10.3390/v16101524.

Whole genome sequencing and phylogenetic analysis of SARS-CoV-2 strains isolated during the COVID-19 pandemic in Nigeria.

IJID Reg. 2024 Jan 17;10:174-178. doi: 10.1016/j.ijregi.2024.01.005. eCollection 2024 Mar.

Bayesian Inference Elucidates the Catalytic Competency of the SARS-CoV-2 Main Protease 3CL.

Anal Chem. 2023 Oct 10;95(40):14981-14989. doi: 10.1021/acs.analchem.3c02459. Epub 2023 Sep 26.

Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness HSPGs: A review and mechanistic hypothesis.

Front Public Health. 2022 Aug 24;10:952916. doi: 10.3389/fpubh.2022.952916. eCollection 2022.

A Biosensor Platform for Point-of-Care SARS-CoV-2 Screening.

Biosensors (Basel). 2022 Jul 3;12(7):487. doi: 10.3390/bios12070487.

Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV.

Med Oncol. 2022 Apr 10;39(6):104. doi: 10.1007/s12032-022-01700-4.

Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.

Clin Microbiol Infect. 2022 Jun;28(6):882.e1-882.e7. doi: 10.1016/j.cmi.2022.02.030. Epub 2022 Mar 3.

ACE2-based capacitance sensor for rapid native SARS-CoV-2 detection in biological fluids and its correlation with real-time PCR.

Biosens Bioelectron. 2022 Apr 15;202:114021. doi: 10.1016/j.bios.2022.114021. Epub 2022 Jan 21.

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.

Cell Rep. 2022 Jan 18;38(3):110256. doi: 10.1016/j.celrep.2021.110256. Epub 2021 Dec 23.

In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern.

Int J Pept Res Ther. 2022;28(1):28. doi: 10.1007/s10989-021-10339-0. Epub 2021 Dec 13.

本文引用的文献

Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2.

Nat Commun. 2021 Sep 27;12(1):5654. doi: 10.1038/s41467-021-25903-x.

Updated SARS-CoV-2 single nucleotide variants and mortality association.

J Med Virol. 2021 Dec;93(12):6525-6534. doi: 10.1002/jmv.27191. Epub 2021 Jul 16.

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.

Nat Commun. 2021 May 17;12(1):2893. doi: 10.1038/s41467-021-23173-1.

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.

A human coronavirus evolves antigenically to escape antibody immunity.

PLoS Pathog. 2021 Apr 8;17(4):e1009453. doi: 10.1371/journal.ppat.1009453. eCollection 2021 Apr.

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.

Science. 2021 Mar 25;372(6549):1413-8. doi: 10.1126/science.abg9175.

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.

The effect of spike mutations on SARS-CoV-2 neutralization.

Cell Rep. 2021 Mar 23;34(12):108890. doi: 10.1016/j.celrep.2021.108890. Epub 2021 Mar 6.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.

Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.

The challenge of emerging SARS-CoV-2 mutants to vaccine development.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

The challenge of emerging SARS-CoV-2 mutants to vaccine development.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献